secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-032272
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Biosciences Q2 2024 net loss $2.0M; PF614-MPAR Phase 1b and OUD candidate PF9001 advance
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders was $2.0M in Q2 2024 vs $2.2M in Q2 2023.
- Cash and cash equivalents totaled $1.0M at June 30, 2024, down from $1.1M at year-end 2023.
- R&D expense fell to $0.9M from $1.6M YoY, driven by lower clinical and pre-clinical costs.
- PF614-MPAR Phase 1b study (PF614-MPAR-102) progressing with Quotient Sciences; overdose protection verification planned.
- PF9001 selected as lead OUD candidate in June; supported by NIH/NIDA HEAL award up to $15M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/0001493152-24-032272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224032272/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer